A research team identified three genes connected to a rare form of childhood leukaemia and found that clinically available drugs had a positive influence on these genes in tests on mice, increasing rates of survival. Read more: https://www.innovationnewsnetwork.com/repurposed-drugs-could-improve-treatment-for-rare-infant-leukaemia/68964/

Now, Cincinnati Children’s is working with New Zealand-based BioOra, Ltd, to launch a clinical trial that would bring a lower-risk, “third-generation” CAR-T therapy—called Alta-cel—to children and teens with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL). Read more: https://scienceblog.cincinnatichildrens.org/clinical-trial-to-evaluate-safer-car-t-cell-therapy-for-children/

Researchers in Japan find that B-cell acute lymphoblastic leukemia with NUTM1 gene rearrangements is a unique form of the disease, with a distinct pattern of gene activity and gene regulation that is highly sensitive to chemotherapy. Read more: https://www.asiaresearchnews.com/content/nutm1-rearrangements-cause-highly-treatable-form-infant-leukemia

The new paper reveals for the first time that these DNA fragments can persist in cancer cells and may drive relapse in patients with...

By characterizing B-cells’ developmental stages, scientists at St. Jude Children’s Research Hospital designed and tested a drug...

Besponsa provides another — and potentially more effective — option outside of traditional chemotherapy for pediatric patients with...

A recent collaboration with colleagues in Shanghai Children’s Medical Center has found a new immunotherapy combination that resulted in ...

An international research team coordinated by Dr. Oscar Molina and Dr. Pablo Menéndez, from the Josep Carreras Leukaemia Research ...

New work finds that the cells that cause relapse in MLL-rearranged B-ALL can morph between two states, and that targeting one of these...

Scientists at St. Jude Children’s Research Hospital and the Cancer Research Center in Spain blocked development of acute lymphoblastic...